SHANGHAI – London-based Glaxosmithkline plc is on the hunt for new ways to treat brain diseases and has found an academic partner in the Sanford Burnham Prebys Medical Discovery Institute (SBP), of La Jolla, Calif.
SHANGHAI – Hutchison China Meditech Ltd., or Chi-Med, has begun human trials for HMPL-689, a PI3K delta blocker for the potential treatment of blood cancers that it hopes can be best in class by overcoming a rival’s safety issues. The trial kicked off in Australia dosing 50 healthy volunteers.
SHANGHAI – Hutchison China Meditech Ltd., or Chi-Med, has begun human trials for HMPL-689, a PI3K delta blocker for the potential treatment of blood cancers that it hopes can be best in class by overcoming a rival's safety issues. The trial kicked off in Australia dosing 50 healthy volunteers.
SHANGHAI – Juno Therapeutics inc., of Seattle, has decided to make its mark in China by partnering with Shanghai-based Wuxi Apptec, a contract research service platform, to build a new company from the ground up, dubbed JW Biotechnology (Shanghai) Ltd.
SHANGHAI – Juno Therapeutics inc., of Seattle, has decided to make its mark in China by partnering with Shanghai-based Wuxi Apptec, a contract research service platform, to build a new company from the ground up, dubbed JW Biotechnology (Shanghai) Ltd.
SHANGHAI – In China, meeting the country's unmet medical needs is a frequent topic of discussion. For biopharmas, that can mean filling the substantial gap between which drugs are available in developed markets and which are available for patients here.
SHANGHAI – While there may be choppy waters all around – growth slowing in China and public markets no longer guaranteeing a safe haven for high valuation exits – China's health care industry is still thought to be a solid bet for investors, according to sentiment from the 7th China Healthcare Investment Conference.
SHANGHAI – In China, meeting the country's unmet medical needs is a frequent topic of discussion. For biopharmas, that can mean filling the substantial gap between which drugs are available in developed markets and which are available for patients here.
SHANGHAI – While there may be choppy waters all around – growth slowing in China and public markets no longer guaranteeing a safe haven for high valuation exits – China's health care industry is still thought to be a solid bet for investors, according to sentiment from the 7th China Healthcare Investment Conference.
SHANGHAI – While perusing the list of China’s most promising biopharmaceutical companies, a surprising fact emerges: Many are not registered in China as purely domestic firms, but operate here as wholly foreign-owned enterprises under a Cayman Islands holding company. Cayman Islands is a well-known business-friendly tax haven.
